GLP-1受体激动剂在糖尿病心肌病中的心血管保护作用：机制和临床前景

doi:10.12092/j.issn.1009-2501.2026.06.002

摘要/Abstract

摘要：

糖尿病心肌病（diabetic cardiomyopathy，DCM）是糖尿病患者常见的心血管并发症，尤其在2型糖尿病患者中更为普遍。尽管近年来针对糖尿病的降糖治疗取得了显著进展，但常规药物仍难以有效延缓糖尿病心肌病的进展。胰高糖素样肽-1受体激动剂（glucagon-like peptide-1 receptor agonists，GLP-1RAs）为新型肠促胰岛素类药物，不仅用于治疗2型糖尿病和肥胖症，还具有显著的心脏和代谢保护作用，能够降低糖尿病患者心血管不良事件的发生风险。本文综述了DCM的病理生理机制，并重点探讨了GLP-1RAs在DCM中的降糖外保护作用机制及其最新临床研究进展。

关键词: 糖尿病心肌病, GLP-1受体激动剂, 糖尿病心血管并发症

Abstract:

Diabetic cardiomyopathy (DCM) is a common cardiovascular complication in diabetic patients, especially more prevalent in patients with type 2 diabetes mellitus. Although remarkable progress has been made in hypoglycemic therapy for diabetes in recent years, conventional drugs still fail to effectively delay the progression of diabetic cardiomyopathy. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are novel incretin-based medications, which are not only used for the treatment of type 2 diabetes mellitus and obesity, but also exert significant cardioprotective and metabolic protective effects, and can reduce the risk of adverse cardiovascular events in diabetic patients. This paper reviews the pathophysiological mechanisms of DCM, and focuses on the extra-hypoglycemic protective mechanisms of GLP-1RAs in DCM as well as the latest advances in clinical research.

Key words: diabetic cardiomyopathy, GLP-1 receptor agonists, diabetic cardiovascular complications

中图分类号:

R542.2

徐晓曼, 周蕾. GLP-1受体激动剂在糖尿病心肌病中的心血管保护作用：机制和临床前景[J]. 中国临床药理学与治疗学, 2026, 31(6): 729-734.

Xiaoman XU, Lei ZHOU. Cardiovascular protective effects of GLP-1 receptor agonists in diabetic cardiomyopathy: mechanisms and clinical prospects[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 729-734.

参考文献 45

1	Seferović PM, Paulus WJ, Rosano G, et al. Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases[J]. Eur J Heart Fail, 2024, 26 (9): 1893- 1903. doi: 10.1002/ejhf.3347
2	Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy[J]. Nat Rev Endocrinol, 2016, 12 (3): 144- 153. doi: 10.1038/nrendo.2015.216
3	Jia G, Habibi J, Bostick BP, et al. Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet[J]. Hypertension, 2015, 65 (3): 531- 539. doi: 10.1161/HYPERTENSIONAHA.114.04737
4	Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome[J]. Med Clin North Am, 2007, 91 (6): 1063- 1077. doi: 10.1016/j.mcna.2007.06.012
5	Ramasubbu K, Devi Rajeswari V. Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review[J]. Mol Cell Biochem, 2023, 478 (6): 1307- 1324. doi: 10.1007/s11010-022-04587-x
6	Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance[J]. J Clin Invest, 1995, 95 (5): 2409- 2415. doi: 10.1172/jci117936
7	Seale LA, Hashimoto AC, Kurokawa S, et al. Disruption of the selenocysteine lyase-mediated selenium recycling pathway leads to metabolic syndrome in mice[J]. Mol Cell Biol, 2012, 32 (20): 4141- 4154. doi: 10.1128/MCB.00293-12
8	Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction[J]. Nat Rev Cardiol, 2017, 14 (1): 30- 38. doi: 10.1038/nrcardio.2016.163
9	Jia G, Aroor AR, Martinez-Lemus LA, et al. Overnutrition, mTOR signaling, and cardiovascular diseases[J]. Am J Physiol Regul Integr Comp Physiol, 2014, 307 (10): 1198- 1206. doi: 10.1152/ajpregu.00262.2014
10	DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity[J]. Nat Rev Endocrinol, 2014, 10 (6): 364- 376. doi: 10.1038/nrendo.2014.44
11	Nistala R, Sowers JR. Hypertension: synergy of antihypertensives in elderly patients with CKD[J]. Nat Rev Nephrol, 2013, 9 (1): 13- 15. doi: 10.1038/nrneph.2012.264
12	Kim JA, Jang HJ, Martinez-Lemus LA, et al. Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation[J]. Am J Physiol Endocrinol Metab, 2012, 302 (2): 201- 208. doi: 10.1152/ajpendo.00497.2011
13	Zhao Y, Hu X, Zhou L, et al. GLP-1 receptor agonists alleviate diabetic cardiomyopathy via Sirt3-dependent mitochondrial quality control[J]. Cardiovasc Diabetol, 2024, 23 (1): 128.
14	Falcão-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment[J]. Heart Fail Rev, 2012, 17 (3): 325- 344. doi: 10.1007/s10741-011-9257-z
15	Peng ML, Fu Y, Wu CW, et al. Signaling pathways related to oxidative stress in diabetic cardiomyopathy[J]. Front Endocrinol (Lausanne), 2022, 13, 9077- 9157.
16	Hashiesh HM, Azimullah S, Nagoor Meeran MF, et al. Cannabinoid 2 receptor activation protects against diabetic cardiomyopathy through inhibition of AGE/RAGE-induced oxidative stress, fibrosis, and inflammasome activation[J]. J Pharmacol Exp Ther, 2024, 391 (2): 241- 257. doi: 10.1124/jpet.123.002037
17	Ridker PM, Everett BM, Thuren T, et al. CANTOS Trial Group. Anti-inflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med, 2017, 377 (12): 1119- 1131.
18	Smith NK, Hackett TA, Galli A, et al. GLP-1: molecular mechanisms and outcomes of a complex signaling system[J]. Neurochem Int, 2019, 128, 94- 105. doi: 10.1016/j.neuint.2019.04.010
19	Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1[J]. Cell Metab, 2018, 27 (4): 740- 756. doi: 10.1016/j.cmet.2018.03.001
20	Zhao X, Wang M, Wen Z, et al. GLP-1 receptor agonists: beyond their pancreatic effects[J]. Front Endocrinol (Lausanne), 2021, 12, 721- 135.
21	Alobaid SM, Alshahrani RM, Alonazi AS, et al. Liraglutide attenuates diabetic cardiomyopathy via the ILK/PI3K/AKT/PTEN signaling pathway in rats with streptozotocin-induced type 2 diabetes mellitus[J]. Pharmaceuticals (Basel), 2024, 17 (3): 374. doi: 10.3390/ph17030374
22	Gerstein HC, Colhoun HM, Dagenais GR, et al. REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial[J]. Lancet, 2019, 394 (10193): 121- 130. doi: 10.1016/S0140-6736(19)31149-3
23	Sazgarnejad S, Yazdanpanah N, Rezaei N. Anti-inflammatory effects of GLP-1 in patients with COVID-19[J]. Expert Rev Anti Infect Ther, 2022, 20 (3): 373- 381. doi: 10.1080/14787210.2021.1964955
24	Mercadante S, Al-Husinat L. Palliative care in amyotrophic lateral sclerosis[J]. J Pain Symptom Manage, 2023, 66 (4): 485- 499. doi: 10.1016/j.jpainsymman.2023.06.029
25	Mittal M, Siddiqui MR, Tran K, et al. Reactive oxygen species in inflammation and tissue injury[J]. Antioxid Redox Signal, 2014, 20 (7): 1126- 1167. doi: 10.1089/ars.2012.5149
26	Ojima A, Ishibashi Y, Matsui T, et al. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression[J]. Am J Pathol, 2013, 182 (1): 132- 141. doi: 10.1016/j.ajpath.2012.09.016
27	Dowsett L, Higgins E, Alanazi S, et al. ADMA: a key player in the relationship between vascular dysfunction and inflammation in atherosclerosis[J]. J Clin Med, 2020, 9 (9): 3026. doi: 10.3390/jcm9093026
28	Pekarova M, Kubala L, Martiskova H, et al. Asymmetric dimethylarginine regulates the lipopolysaccharide-induced nitric oxide production in macrophages by suppressing the activation of NF-kappaB and iNOS expression[J]. Eur J Pharmacol, 2013, 713 (1-3): 68- 77. doi: 10.1016/j.ejphar.2013.05.001
29	Luna-Marco C, Iannantuoni F, Hermo-Argibay A, et al. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress[J]. Free Radic Biol Med, 2024, 213, 19- 35. doi: 10.1016/j.freeradbiomed.2024.01.015
30	Zhong J, Chen H, Liu Q, et al. GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation[J]. J Pharm Anal, 2024, 14 (5): 1009- 1017. doi: 10.1016/j.jpha.2023.12.007
31	Fang P, Ye Z, Li R, et al. Glucagon-like peptide-1 receptor agonist protects against diabetic cardiomyopathy by modulating microRNA-29b-3p/SLMAP[J]. Drug Des Devel Ther, 2023, 17, 791- 806. doi: 10.2147/DDDT.S400249
32	Cai H, Zhou L, Liu J, et al. Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic cardiomyopathy rats[J]. Biochem Biophys Res Commun, 2022, 629, 112- 120. doi: 10.1016/j.bbrc.2022.09.018
33	Butler J, Shah SJ, Petrie MC, et al. STEP-HFpEF Trial Committees and Investigators. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials[J]. Lancet, 2024, 403 (10437): 1635- 1648. doi: 10.1016/S0140-6736(24)00469-0
34	Shaman AM, Bain SC, Bakris GL, et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER[J]. Circulation, 2022, 145 (8): 575- 585. doi: 10.1161/CIRCULATIONAHA.121.055459
35	Perkovic V, Tuttle KR, Rossing P, et al. FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes[J]. N Engl J Med, 2024, 391 (2): 109- 121. doi: 10.1056/NEJMoa2403347
36	Landin-Olsson M. Effect of liraglutide on beta-cell function in latent autoimmune diabetes in adults: a randomized clinical trial[J]. Diabetes Care, 2019, 42 (7): 1269- 1275.
37	Wilding JPH. Once-weekly semaglutide in adults with overweight or obesity[J]. N Engl J Med, 2021, 384 (11): 989- 1002. doi: 10.1056/NEJMoa2032183
38	Marso SP. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016, 375 (4): 311- 322. doi: 10.1056/NEJMoa1603827
39	Verma S. Semaglutide in heart failure with preserved ejection fraction and diabetes: insights from STEP-HFpEF DM [J]. Lancet Diabetes Endocrinol, 2024, 12(7): 489-498.
40	Zhang Y, Li J, Chen H, et al. Dual GIP/GLP-1 receptor agonist tirzepatide improves cardiac function and myocardial metabolism in diabetic cardiomyopathy[J]. J Mol Cell Cardiol, 2025, 96, 113245.
41	Perkovic V. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med, 2019, 380 (15): 1407- 1419.
42	Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study[J]. Lancet, 2002, 359 (9309): 824- 830. doi: 10.1016/S0140-6736(02)07952-7
43	Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists[J]. Front Endocrinol (Lausanne), 2024, 15, 1431- 292.
44	Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Management in CKD [J]. Kidney Int, 2022, 102(5): 120-127.
45	American Diabetes Association. Standards of Medical Care in Diabetes-2023[J]. Diabetes Care, 2023, 46 (1): 290- 294.

[1]	黄淑敏, 谢保城, 刘国辉. GLP-1受体激动剂治疗糖尿病肾病作用机制的研究进展[J]. 中国临床药理学与治疗学, 2025, 30(12): 1701-1710.
[2]	王文娟, 齐鸣瑞, 田利民. Nrf2在糖尿病心肌病中的作用及中药干预研究进展[J]. 中国临床药理学与治疗学, 2022, 27(10): 1163-1170.
[3]	王晓琳, 高攀, 邹云增. 线粒体氧化应激与糖尿病心肌病的关系[J]. 中国临床药理学与治疗学, 2021, 26(9): 1080-1085.
[4]	张伟萍, 江建军, 陈晓锋, 许莎莎. 栀子苷通过抑制VPO1/ERK1/2信号通路减轻糖尿病心肌病大鼠的心肌细胞凋亡[J]. 中国临床药理学与治疗学, 2021, 26(2): 129-136.
[5]	张翠，张根葆，王继胜，陆晓华，李曙. 芒果苷对糖尿病大鼠心肌的保护作用[J]. 中国临床药理学与治疗学, 2016, 21(8): 859-862.